KPV
KPV (Lysine–Proline–Valine) is a C‑terminal tripeptide fragment of α‑melanocyte‑stimulating hormone (α‑MSH) studied for its potent anti‑inflammatory properties without melanotropic side effects. Research demonstrates KPV reduces pro‑inflammatory cytokines in models of inflammatory bowel disease and systemic inflammation. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for precise insulin‑syringe measurements.Selank is a synthetic heptapeptide based on the naturally occurring tuftsin sequence. Human research has evaluated intranasal Selank in adults with generalized anxiety disorder, neurasthenia, and in acute neuroimaging experiments. The calculations below use the entire 10 mg vial and keep published study protocols separate from worked preparation examples.
Reconstitution Steps
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Protocol Overview
Concise summary of the once-daily regimen based on clinical trial designs.
Goal: Support reduction of systemic inflammation and modulate immune responses without melanotropic effects
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Dose Range: 200–500 mcg daily with gradual weekly titration.
Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
Storage: Lyophilized frozen at −20 °C (−4 °F) or below; reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw.
Dosing Protocol
Suggested daily titration approach reflecting clinical study parameters.
Start: 200 mcg daily; increase by ~100 mcg weekly as tolerated
Target: 400–500 mcg daily by Weeks 4–8 for maintenance anti‑inflammatory effects.
Frequency: Once per day (subcutaneous).
Cycle Length: 8–12 weeks; optional extension to 16 weeks under monitoring.
Timing: Any consistent time; rotate injection sites systematically.
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at 2–8 °C (35.6–46.4 °F); for long-term storage, −20 °C (−4 °F) is acceptable.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~30 days; avoid freeze–thaw cycles.
Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
Use new sterile insulin syringes for each administration; dispose in a sharps container immediately after use.
Rotate injection sites systematically (abdomen, thighs, upper arms) at least 1–2 inches apart to reduce local irritation and prevent lipohypertrophy
Inject slowly; wait a few seconds before withdrawing the needle to prevent solution backflow.
Document daily dose, injection site, and any observations to maintain consistency and track tolerability.
If injection‑site reactions (redness, mild swelling) occur, apply a cool compress and monitor; persistent reactions warrant protocol review.
How This Works
KPV is the C‑terminal tripeptide sequence (residues 11–13) of α‑melanocyte‑stimulating hormone (α‑MSH), retaining potent anti‑inflammatory activity without the hormone’s melanotropic effects. Preclinical studies demonstrate KPV reduces pro‑inflammatory cytokines (TNF‑α, IL‑6, IL‑1β) and modulates immune cell activity in models of inflammatory bowel disease, colitis, and systemic inflammation. The peptide’s mechanism involves inhibition of nuclear factor kappa B (NF‑κB) signaling and modulation of inflammatory mediator release. Subcutaneous administration provides systemic delivery with rapid absorption and sustained anti‑inflammatory effects observed in daily dosing protocols.
Potential Benefits & Side Effects
Observations from preclinical and clinical literature.
Anti‑inflammatory activity: Reduces pro‑inflammatory cytokines and modulates immune responses in models of inflammatory bowel disease and systemic inflammation
Oral and subcutaneous efficacy: Multiple routes of administration show activity, with subcutaneous injection favored for systemic delivery and consistent bioavailability
Wound healing support: Preclinical data suggest KPV may support tissue repair and wound healing processes through inflammatory modulation
Generally well tolerated: Occasional mild injection‑site reactions (redness, slight swelling) may occur; systemic side effects are rarely reported in research protocols.
No melanotropic effects: Unlike full α‑MSH, KPV does not affect melanocyte activity or skin pigmentation
Lifestyle Factors
Complementary strategies that may support therapeutic goals.
Pair with a balanced, protein-adequate diet to support muscle synthesis and recovery.
Combine resistance training and cardiovascular exercise to maximize anabolic and metabolic benefits.
Prioritize 7–9 hours of quality sleep nightly, as GH naturally peaks during deep sleep phases.
Manage stress levels, as chronic stress and elevated cortisol can blunt GH response.
Inject on an empty stomach (avoid food 2–3 hours before and 30–60 minutes after) to optimize GH release.
Injection Technique
General subcutaneous guidance from clinical best-practice resources.
Clean your hands and work on a clean surface.
Swab the vial’s rubber stopper and injection site with alcohol; allow to dry.
Draw the calculated dose into the insulin syringe, eliminating air bubbles.
Suitable SC injection areas include the abdomen (2 inches from navel), outer thighs, upper outer arms, or flank/hip area.
Pinch a fold of skin between thumb and forefinger; insert the needle at 45–90° into subcutaneous tissue.
Do not aspirate for subcutaneous injections; inject slowly and steadily.
After injection, release the pinched skin and withdraw the needle at the same angle.
Apply gentle pressure with a clean cotton or alcohol pad; do not rub vigorously.
Rotate sites systematically with each dose to prevent irritation or tissue damage.
Immediately dispose of the used syringe in a proper sharps container.
